Literature DB >> 3547130

Hypertrophic cardiomyopathy. Interrelations of clinical manifestations, pathophysiology, and therapy (1).

B J Maron, R O Bonow, R O Cannon, M B Leon, S E Epstein.   

Abstract

Entities:  

Mesh：

Year:  1987        PMID： 3547130     DOI： 10.1056/NEJM198703263161305

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  107 in total

1.  Echocardiographic pitfalls in the diagnosis of hypertrophic cardiomyopathy.

Authors:  K Prasad; J Atherton; G C Smith; W J McKenna; M P Frenneaux; P Nihoyannopoulos
Journal:  Heart       Date:  1999-11       Impact factor: 5.994

Review 2.  Cardiomyopathy: The diagnosis of hypertrophic cardiomyopathy.

Authors:  E D Wigle
Journal:  Heart       Date:  2001-12       Impact factor: 5.994

3.  Stress-induced changes in subendocardial tissue texture in hypertrophic cardiomyopathy: an echocardiographic videodensitometric study.

Authors:  A Pingitore; E Picano; M Paterni; M Passera
Journal:  Int J Cardiovasc Imaging       Date:  2001-08       Impact factor: 2.357

4.  Transthoracic Doppler echocardiographic analysis of phasic coronary blood flow velocity in hypertrophic cardiomyopathy.

Authors:  J J Crowley; P S Dardas; A A Harcombe; L M Shapiro
Journal:  Heart       Date:  1997-06       Impact factor: 5.994

5.  Transient right sided hypertrophic cardiomyopathy in an infant born to a diabetic mother.

Authors:  A Akcoral; B Oran; V Tavli; H Oren; N T Cevik
Journal:  Indian J Pediatr       Date:  1996 Sep-Oct       Impact factor: 1.967

Review 6.  Fibrosis in heart disease: understanding the role of transforming growth factor-beta in cardiomyopathy, valvular disease and arrhythmia.

Authors:  Razi Khan; Richard Sheppard
Journal:  Immunology       Date:  2006-05       Impact factor: 7.397

7.  MRI classification of asymmetric septal hypertrophic cardiomyopathy and its relation to the presence of risk factors.

Authors:  Yasuo Amano; Mitsunobu Kitamura; Morimasa Takayama; Masaki Tachi; Shinichiro Kumita
Journal:  Int J Cardiovasc Imaging       Date:  2012-03-04       Impact factor: 2.357

8.  Abnormal skeletal muscle bioenergetics in familial hypertrophic cardiomyopathy.

Authors:  C H Thompson; G J Kemp; D J Taylor; M Conway; B Rajagopalan; A O'Donoghue; P Styles; W J McKenna; G K Radda
Journal:  Heart       Date:  1997-08       Impact factor: 5.994

9.  Effects of hypertrophy and fibrosis on regional and global functional heterogeneity in hypertrophic cardiomyopathy.

Authors:  Sung-A Chang; Sang-Chol Lee; Yeon Hyeon Choe; Hye-Jin Hahn; Shin Yi Jang; Sung-Ji Park; Jin-Oh Choi; Seung Woo Park; Jae K Oh
Journal:  Int J Cardiovasc Imaging       Date:  2012-10-25       Impact factor: 2.357

10.  Plasminogen activator inhibitor-1 (PAI-1) is cardioprotective in mice by maintaining microvascular integrity and cardiac architecture.

Authors:  Zhi Xu; Francis J Castellino; Victoria A Ploplis
Journal:  Blood       Date:  2009-12-15       Impact factor: 22.113
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.